FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

BMS sources discount chance of Sanofi buyout

Dow Jones is quoting sources close to Bristol-Myers Squibb who say that a buyout by Sanofi-Aventis is not in the cards. BMS is betting on its pipeline for its future expansion, says the source. The possibility of a tie-up has caused considerable buzz in the M&A field, especially as Sanofi-Aventis has indicated its interest in snapping up a pharma and biotech company. A deal between BMS and Sanofi looked particularly compelling because it would have expanded the French company's U.S. reach while advancing relations between two companies with a long history of collaborating on drug projects. One of those projects includes the blockbuster Plavix, which was the subject of a closely watched patent lawsuit and will remain under patent protection until 2011.

- check out the CNN report

Related Articles:
Report: Sanofi-Aventis inks preliminary deal for BMS. Report
Patent victory reignites rumors of BMS takeover. Report
Rumor Mill: Is BMS going on the sales block? Report
Analysts buzzing about possible Bristol-Myers sale. Report
More details emerge on secret Plavix pact. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:
Be the first to comment
More stories about Plavix   Sanofi-Aventis   Mergers and Acquisitions   pharmaceuticals   pipeline   patent   Bristol-Myers Squibb  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.